Biomol Ther.  2017 Sep;25(5):461-470. 10.4062/biomolther.2016.271.

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

• Kim JH
• Lim KM
• Gwak HS

• KMID: 2389377
• DOI: http://doi.org/10.4062/biomolther.2016.271

Abstract

Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.

Keyword

Anticoagulant; Vitamin K antagonist; Heparin; Venous thromboembolism

MeSH Terms

Anticoagulants*
Drug Interactions
Hemorrhage
Heparin
Venous Thromboembolism*
Vitamin K
Anticoagulants
Heparin
Vitamin K